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Abstract 
Objective. Human cutaneous melanoma is an aggressive and chemotherapy resistant type of cancer. 
AM251 is a cannabinoid type 1 (CB1) receptor antagonist/inverse agonist with off-target antitumor 
activity against pancreatic and colon cancer cells. The current study is aimed at characterizing the in 
vitro anti-melanoma activity of AM251. 
Methods. The BRAF V600E mutant melanoma cell line, A375, was used as an in vitro model 
system. Characterization tools included cell viability assay, nuclear morphology assessment, gene 
expression, western blot, flow cytometry with annexin V-FITC/ 7-AAD double staining, cell cycle 
analyses, measurements of changes in intracellular cAMP and calcium concentrations.  
Results. AM251 exerted a remarkable cytotoxic effect against A375 human melanoma cells with 
potency comparable to that observed for cisplatin without significant changes on the human dermal 
fibroblasts viability. AM251, at a concentration that approximates the IC50, downregulated genes 
encoding anti-apoptotic proteins (BCL2 and Survivin) and increased transcription levels of pro-
apoptotic BAX, induced alteration of annexin V reactivity, DNA fragmentation, chromatin 
condensation in the cell nuclei, and G2/M phase arrest. AM251 also induced a 40% increase in the 
basal cAMP levels while it did not affect intracellular calcium concentrations. The involvement of 
GPR55, TRPA1, and COX-2 in the AM251 mechanism of action was excluded. Combination of 
AM251 with celecoxib produced a synergistic antitumor activity although the mechanism 
underlying this effect remains to be elucidated. 
Conclusions. This study provides the first evidence of a pro-apoptotic effect and G2/M cell cycle 
arrest of AM251 on A375 cells. This compound may be a potential prototype for the development 
of promising diarylpyrazole derivatives to be evaluated in human cutaneous melanoma.  
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Introduction 
Cutaneous melanoma, the malignant tumor of melanocytes, is the skin cancer with the greatest 
mortality and an increasing incidence worldwide [1]. About 50% of melanomas contain a mutation 
in the proto-oncogene encoding for the serine/threonine kinase B-raf (BRAF) that leads to 
constitutive activation of downstream signaling in the MAP kinase pathway. In a high percentage of 
cases, the activating mutation consists of the substitution of valine for glutamate at amino acid 600 
(V600E) [2,3], a phenotype correlating with bad prognosis in metastatic melanoma patients [4]. The 
inhibition of oncogenic B-raf by targeted drugs induces short-lived clinical responses due to the 
reactivation of signaling downstream of B-raf and the development of acquired resistance in BRAF 
mutant melanoma patients [5,6]. These notions highlight the need for identification of new 
prototype compounds aimed at increasing the therapeutic armamentarium for this type of cancer. 
Although it is prevalently used as cannabinoid (CB) 1 receptor antagonist/inverse agonist, several 
lines of evidence demonstrated that the pharmacological profile of the diarylpyrazole derivative 
AM251 is also characterized by CB-independent biological actions [7-13]. Noteworthy, a 
remarkable anticancer activity of AM251 has been documented in pancreatic [7,9] and colon cancer 
cells [9].  
The aim of the present study was to characterize the anti-melanoma activity of AM251 against the 
BRAF V600E mutant cell line, A375, in terms of proapototic activity and mechanism of action.  
 
 
Methods 
Cell cultures 
The human melanoma A375 cell line (American Type Culture Collection, Rockville, MD, USA) 
was cultured at 37°C in a humidified atmosphere containing 5% CO2 in DMEM supplemented with 
l-glutamine (2 mM), 10% heat-inactivated fetal bovine serum (FBS) and 1% (w/v) 
penicillin/streptomycin (Sigma-Aldrich, Milan, Italy). Adult human dermal fibroblasts (HDFa; Ref. 
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C-013-5C, Gibco, Life Technologies, CA, USA) were cultured in an optimized medium containing 
5% fetal bovine serum (FBS) and 1% (w/v) penicillin/streptomycin, as recommended by the 
manufacturer.  
 
Drugs 
AM251 (selective CB1 receptor antagonist/inverse agonist and GPR55 agonist), CID16020046 
(selective GPR55 antagonist) and forskolin (adenylyl cyclase activator) were obtained from Tocris 
Bioscience (Northpoint, UK). Cisplatin (CisPt), L-α-lysophosphatidylinositol (LPI), celecoxib, 
rofecoxib and indomethacin were purchased from Sigma–Aldrich, Milan, Italy. Compounds were 
dissolved in their specific solvents (DMSO for AM251, CID16020046, LPI and rofecoxib, water 
for Cis-Pt, and ethanol for others) and further diluted in sterile culture medium immediately before 
their use. DMSO did never exceed 0.33% v/v in the culture medium. 
 
Cell viability assay  
Cell viability was measured using a method based on the cleavage of the 4-(3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolium)-1,3-benzene disulfonate (WST-1) to formazan by mitochondrial 
dehydrogenase activity following manufacturer's instructions (Cell proliferation reagent WST-1; 
Roche, Mannheim, Germany). Briefly, cells (5×104/well) were seeded in 96-well plate in 10% FBS 
medium; after 24 h, the complete medium was replaced with compound-containing 1% FBS 
medium. Each compound was dissolved in its specific solvent and then diluted in medium up to the 
concentrations to be tested. Freshly stock solutions were prepared. AM251 was tested in a 
concentration range of 0.1–50 µM for 24-72 h and its effects evaluated in the presence or absence 
of different antagonists, selective or non-selective COX-2 inhibitors added 2 h before.  
After drug treatment, WST-1 was added and, after 1 h, the absorbance was measured at 450 nm 
using Infinite® M200 NanoQuant instrument (Tecan, Salzburg, Austria). Optical density values 
from vehicle-treated cells were considered as 100% cell viability. 
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Transfection  
Cells were transfected with GPR55 siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, 
sc-75183) according to the manufacturer’s instructions. Briefly, cells were transfected with 100 nM 
siRNA using Lipofectamine 2000 (Ref. 11668-027, Invitrogen Life Technologies, Carlsbad, CA, 
USA), which has been reported to yield high transfection efficiency (≈70%) in A375 cells [14]. A 
scrambled non-specific siRNA fluorescent conjugate (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA, sc-36869) was used as control and for preliminary confirmation of transfection 
efficiency through microscope analysis.  
 
RT-PCR and quantitative real-time PCR analyses 
Total RNA from cells was extracted by using the RNeasy® Mini kit, following manufacturer’s 
instructions, and reverse-transcribed by the QuantiTect® Reverse Transcription kit (Qiagen, 
Valencia, CA, USA). RT-PCRs were performed by the HotStartTaq Master Mix kit (Qiagen, 
Valencia, CA, USA). Primer sequences are listed in Table 1. Thermal cycle conditions were as 
follows: 95°C for 15 min, 35 cycles of denaturation at 95°C for 1 min followed by annealing and 
extension at 72°C for 1 and 10 min, respectively. Detection of the RT-PCR products was performed 
by agarose gel electrophoresis and ethidium bromide staining.  
Real-time PCR was performed with SsoFast Eva Green Supermix (Ref. 172-5201, Bio-Rad, CA, 
USA). Samples were amplified using the following thermal profile: 95°C for 30 s, 40 cycles of 
denaturation at 95°C 15 s followed by annealing for 30 s and 72°C for 30 s, with a final step at 
65°C for 5 s. β-actin and GAPDH were used as housekeeping genes. 
 
Western blot analysis 
Cell lysates were collected after treatment with AM251 at 5 µM for 48 h. Samples were transferred 
and probed with specific antibodies, as previously reported [15]. Quantification of proteins on SDS-
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PAGE gels was performed using ImageJ densitometry software and signal intensities were 
normalized to those for β-actin. 
 
Annexin V and 7-AAD assay 
Dual staining with Annexin V conjugated to fluorescein-isothiocyanate (FITC) and 7-
aminoactinomyosin (7-AAD) was performed using the commercially available kit (Muse Annexin 
V and Dead Cell Kit; Merk KGaA, Darmstadt, Germany). Briefly, the treated A375 cells (both 
floating and adherent cells) were collected and subjected to Annexin V-FITC and 7-AAD staining. 
MuseTM Cell Analyzer measured the sample fluorescence of 10,000 cells. In cells undergoing 
apoptosis, annexin V bound to phosphatidylserine, which translocated from the inner to the outer 
leaflet of the cytoplasmic membrane. Double staining was used to distinguish between viable, early 
apoptotic, or necrotic or late apoptotic cells.  Annexin V:FITC positive and 7-AAD negative cells 
were identified as early apoptotic while Annexin V:FITC positive and 7-AAD positive cells were 
identified as in late apoptosis or necrosis. 
 
Determination of nuclear morphology 
Changes in nuclear morphology of A375 cells were assessed after treatment with AM251 or its 
vehicle for 48 h. Cells were fixed with 2% paraformaldehyde on 8-well chamber slides. After 
washing with PBS, cells were incubated with DAPI 300 nM (Invitrogen Life Technologies, CA, 
USA ). Fluorescence analysis was realized with Eclipse E600FN Nikon microscope using λex 360 
nm and λem 460 nm (magnification 40 × WD). 
 
cAMP assay 
Intracellular cAMP levels were measured by the cAMP Enzyme Immunoassay Kit (Sigma–Aldrich, 
Milan, Italy) after treatment with AM251 5 µM or forskolin 5 µM as positive control. Cell lysates 
and standards were incubated with a cAMP recognising antibody and incubated at room 
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temperature in a secondary antibody coated multiwell plate. The excess reagents were then washed 
away and substrate added. After the incubation time the enzyme reaction was stopped and the 
yellow color read on a multiwell plate reader at 405 nm (Infinite® M200 NanoQuant; Tecan, 
Salzburg, Austria).  
 
Fluorescent microscope analysis of [Ca2+]i   
Imaging of [Ca2+]i was carried out in A375 cells grown on discs of 35 mm diameter. Fluo-3 AM 
(Ref. F-1242, Molecular probe, Life Technologies, CA, USA) was added to the culture medium, the 
cells were incubated for 30 min at 37°C dark and then washed with medium. After 30 min of de-
esterification, fluorescence analysis was performed with Eclipse E600FN Nikon microscope (water 
dipping objective 40X, λex 490 nm, λem 520 nm) during the perfusion with AM251 and 5 µM 
ionomycin (Calbiochem, Merck Millipore, Darmstadt, Germany) as positive control. The relative 
fluorescence ΔF/F0 was used as an indicator of [Ca2+]i in regions of interest. 
To determine the [Ca2+]i concentrations, Fura-2 AM (Ref. F1201, Molecular probe, Life 
Technologies, CA, USA) was added to the cells previously treated with AM251 or vehicle for 48 h, 
for 30 min at 37°C in the dark. After washing with medium and 30 min of de-esterification, 
fluorescence analysis was performed with Eclipse E600FN Nikon microscope. Loaded cells were 
alternatively excited at 340 and 380 nm while they were imaged at 510 nm. After background 
subtraction, ratio images were obtained by dividing, pixel by pixel, pairs of digitized images at 340 
and 380 nm. Fluorescence values were converted into ion concentrations, according to Grynkiewicz 
et al. (1985) [16]. 
 
Cell Cycle 
The distribution of cells in the different cycle phases was performed using the Muse™ Cell 
Analyzer (Merck KGaA, Darmstadt, Germany). Briefly, A375 cells were treated with AM251 (5 
µM) or its vehicle for 48 and 72 h. Asynchronous adherent cells were collected and centrifuged at 
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300 × g for 5 minutes. The pellet was washed with PBS and re-suspended in 100 µl of PBS; finally 
cells were slowly added to 1 ml of ice cold 70% ethanol and maintained o/n at –20°C. Then, a cell 
suspension aliquot (containing at least 2 × 105 cells) was centrifuged at 300 × g for 5 minutes, 
washed once with PBS and suspended in the fluorescent reagent (Muse™ Cell Cycle reagent). After 
incubation for 30 minutes at room temperature in the dark, measurements of the percentage of cells 
in the different phases were acquired. 
 
Statistical analysis 
All experiments were performed in triplicate and results were analyzed by GraphPad Prism 5 
(GraphPad Software, San Diego, CA, USA). Data were shown as mean values ± standard error of 
the mean (SEM) obtained from at least three separate experiments. Statistical analyses were 
performed by Student's t-test or one-way ANOVA followed by the Bonferroni’s multiple 
comparison test. 
 
Results 
Effect of AM251 on cell viability  
AM251 at 0.1-50 µM for 24-72 h induced a concentration- and time-dependent cytotoxicity in 
A375 cells (Fig. 1A). The IC50 mean value was 5.52 ± 1.08 µM and 1.79 ± 1.42 µM after 48 and 
72 h, respectively, while after 24 h the IC50 was not reached. The IC50 of cisplatin (CisPt), the 
anticancer drug used as reference compound, was 4.33 ± 0.04 µM after 48 h-exposure. Noteworthy, 
the IC50 was never reached in human dermal fibroblasts-adult, HDFa treated with AM251 at 0.1-50 
µM for 48 and 72 h (Fig.1B). 
 
Effect of AM251 on apoptosis 
The role played by the apoptotic process in the AM251-induced cytotoxicity was assessed 
measuring variation in expression of pro-/anti-apoptotic proteins, morphological changes in the cell 
9 
 
nuclei by fluorescence microscopy, annexin-V and 7-AAD cytofluorometric staining and 
intracellular calcium concentrations.  
AM251 at 5 µM for 48 h increased BAX, decreased Survivin and BCL2 gene expression (Fig. 2A), 
and survivin protein expression (Fig. 2B), as compared to controls. Furthermore, AM251 at 5 µM 
for 72 h markedly increased the number of early and late apoptotic fractions (Fig. 2C) and induced 
DNA fragmentation and chromatin condensation in the cell nuclei (Fig. 2D), compared to untreated 
cells.  
The role of intracellular calcium in the pro-apoptotic effect induced by AM251 was investigated 
evaluating the effects of both short and long term treatment of A375 cells. Cells loaded with Fluo-3 
did not exhibit detectable changes of fluorescence during treatment with AM251 at concentrations 
0.1-10 µM, while they responded to ionomycin 5 µM, as shown in Fig. 4E. A375 cells loaded with 
Fura-2 AM and treated with AM251 5 µM or vehicle for 48 h did not differ in their intracellular 
concentration of free calcium, as shown in Fig. 2E.  
 
Effect of AM251 on cell cycle  
The analysis of cell cycle phase distribution of asynchronous cells was assessed by flow cytometry. 
After treatment with AM251 at 5 µM for 48 h the proportion of cells in G0/G1, S and G2/M phases 
of the cell cycle was 59.2, 14.7 and 20.2%, respectively. The comparison with untreated cells 
revealed a significant increase of cells in the G2/M and S phases and a decrease of cells in G1/G0 
phase (Fig. 3A). Prolonged drug exposure (i.e., 72 h) induced a significant decrease of cells also in 
the S phase (Fig. 3B), thus confirming the ability of AM251 to promote a cell cycle arrest at G2/M. 
 
Effect of AM251 on intracellular cAMP levels 
A possible influence on cytosolic cAMP content was evaluated in A375 cells exposed to AM251 at 
5 µM for 48 h. As shown in Fig. 4A, a significant increase (by 40%) in cytosolic cAMP basal levels 
was observed in treated versus untreated cells.  
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Effect of AM251 on GPR55 and TRPA1 
GPR55 has been recognized as the possible “third” cannabinoid receptor [37,38] with a role in 
tumorigenesis and metastasis [39-41]. The role of GPR55 on the mechanism of AM251 action was 
evaluated using gene silencing. 100 nM specific siRNA incubated for 24 and 48 h time-dependently 
reduced GPR55 mRNA expression by 40.9 and 72.8%, respectively, as compared with scrambled 
siRNA treated cells (Fig. 4B). No change was induced by siRNA on AM251-induced cytotoxicity 
(Fig. 4C). Treatment with the potent endogenous GPR55 agonist LPI or the selective GPR55 
antagonist, CID16020046, up to 30 µM for 48h did not significantly affect cell viability (data not 
shown).  
TRPA1 is expressed in A375 cells [17] and could be a possible target for AM251 [8]. After 
confirming the presence of TRPA1 by RT-PCR analysis (Fig. 4D), the role of TRPA1 in the 
AM251-induced cytotoxicity was investigated recording calcium changes immediately after 
treatment in Fluo 3-AM loaded cells. As shown in Fig. 4E, AM251 at 0.1-10 µM did not modify 
intracellular content of calcium ions, while a clear increase was detectable after the administration 
of calcium ionophore ionomycin. 
 
Role of COX-2 in AM251-induced cytotoxicity  
We previously reported that COX enzymes are expressed in A375 cells [46] . In the current study, 
we found that treatment of A375 cells with the selective COX-2 inhibitor celecoxib at 0.1-100 µM 
for 48 h induced cytotoxicity with an IC50 of 35.64 ± 1.03 (Fig. 5A). At variance with this, no 
effect on cell viability was observed when cells were exposed to rofecoxib (selective COX-2 
inhibitor) or indomethacin (non-selective COX inhibitor) (Fig. 5A).  Combination of AM251 at 1 
and 3 µM with selective COX-2 inhibitor, rofecoxib, or non-selective COX-2 inhibitor, 
indomethacin, did not significantly affect cell viability (data not shown). At variance with this, 
AM251 plus celecoxib produced an anti-proliferative activity greater than that observed for each 
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drug alone (Fig. 5B). Such an effect appeared to be synergic because it was greater than the sum of 
the percentage obtained from single treatments. 
 
Discussion  
In the current study, we demonstrated that AM251 exerted a remarkable cytotoxic effect against 
A375 human melanoma cells with potency comparable to that observed for cisplatin. AM251, in the 
concentration range tested against melanoma cells, did not significantly affect the viability of 
proliferating human fibroblasts, suggesting that the compound may exhibit some selectivity for 
cancer cells. To explore in more detail the underlying mechanism of AM251, we assessed whether 
genes encoding for Bcl-2, Bax and survivin were a target of AM251. Bax and Bcl-2 are two 
members of the Bcl-2 family that regulates, with opposite effects, the release of cytochrome c in 
mitochondria-dependent apoptosis [18], whereas survivin is a member of the IAP (inhibiting 
apoptosis protein) family, which inhibits caspase-9 activation, a typical enzyme involved in the 
intrinsic apoptotic pathway. In our experimental conditions, the pro-/anti-apoptotic balance drifted 
to the pro-apoptotic side after treatment of A375 cells with AM251. Specifically, AM251 reduced 
the expression of anti-apoptotic BCL2 and survivin protein and increased transcription levels of 
pro-apoptotic BAX. Furthermore, AM251, at a concentration that approximate the IC50 value 
obtained in cell viability experiments (i.e., 5 µM) induced characteristic features of apoptosis, 
including externalization of phosphatidylserine, DNA fragmentation and chromatin condensation.  
Using real-time imaging with the single-wavelength intensity-modulating dye Fluo 3, we did not 
find changes of intracellular Ca2+ in A375 cells during treatment with AM251 at 0.1-10 µM.  
Moreover, dual-wavelength ratiometric indicator Fura-2 allowed us to measure the [Ca2+]i 
concentrations in cells treated for 48 h  with AM251 5 µM or vehicle, assessing the maintenance of 
the intracellular calcium homeostasis in both experimental conditions. These findings suggest that 
AM251 can induce apoptosis by a specific Ca2+-independent mechanism of action. Interesting to 
note, Gogvadze and co-workers demonstrated a Ca2+-independent mechanism of mithocondria 
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release of cytochrome c via the pro-apoptotic protein Bax [19] and data of the current study showed 
that AM251 significantly increased BAX expression in A375 cells.  
Apoptotic cell death is generally linked to alterations in cell cycle program. The percentage of 
G0/G1 and S-phase  cells was considerably decreased by AM251 and the parallel increase in the 
proportion of cells in G2/M-phase, in treated versus untreated cells, suggests a cell cycle arrest at 
this level. In line with this, drug-induced arrest in the G2 or M phases may be followed by apoptotic 
cell death [20] and a pro-apoptotic G2 arrest has been already described in A375 melanoma cells 
treated with various agents [21-24].  
CB1 coupling to the G protein signal transduction pathways transduces the cannabinoid inhibition 
of adenylyl cyclase, thus attenuating the production of cAMP [25]. It is interesting to note that 
although the in vitro anticancer effect following CB1 receptor activation has been demonstrated in a 
variety of human cancers [26-30], few data have been provided to substantiate the relationship 
between such an effect and inhibition of cAMP formation [31]. On the contrary, activation of cyclic 
nucleotide signaling has been demonstrated to be associated to inhibition of cell proliferation and 
induction of apoptosis in many cancer cell types [32,33]. For example, elevation of cAMP levels 
induced by the adenylate cyclase activator, forskolin, or the phosphodiesterase-4 inhibitor, rolipram, 
induces death of multiple myeloma cells and cAMP-mediated cell death has all the typical 
hallmarks of apoptosis [34]. In line with its recognized mechanism of action as antagonist/partial 
inverse agonist at Gi protein-coupled CB1 receptors [35], we observed a 40% increase in the basal 
cAMP levels on A375 cells treated with a concentration that approximate the IC50 of AM251, 
suggesting a possible role of cAMP elevation in the in vitro anti-melanoma activity of AM251. 
AM251 has been recognized to act as agonist/partial agonist at GPR55, the possible “third” 
cannabinoid receptor [36,37,42,43,44], our findings clearly exclude the involvement of GPR55 in 
the mechanism of AM251 action. Indeed, the potent endogenous GPR55 agonist, LPI [45] did not 
affect A375 cell viability and no difference in AM251 activity was observed in GPR55-silenced 
cells, compared to controls.  
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AM251 has been also reported to activate the transient receptor potential A1 (TRPA1) in sensory 
neurons [8] and TRPA1 was found to be expressed in A375 cells [17], a condition that has also 
been confirmed in the current study. Our findings demonstrated no early rise in [Ca2+]i basal levels 
after treatment of A375 cells with AM251. Since TRPA1 is a non-selective Ca2+ permeable 
channel, the anticancer effect of AM251 was probably independent of TRPA1 channel activation. 
Furthermore, data showing that ionic currents through TRPA1 are unlikely responsible for the anti-
tumour effects of highly potent TRPA1-activating compounds in A375 cells [17], suggest that this 
receptor type does not have a major role in determining the phenotype of human melanoma cells. 
Taking into account the high levels of cyclooxygenase (COX)-2 expressed in A375 cells [46], we 
tried to understand whether COX-2 could play a role in AM251 cytotoxicity. While celecoxib 
induced cytotoxicity in A375 cells, with a potency lower than that observed for AM251, other 
selective (rofecoxib) and non-selective (indomethacin) COX-2 inhibitors did not. Combination of 
AM251 with rofecoxib or indomethacin did not significantly affect cell viability, whereas AM251 
plus celecoxib dysplayed synergistic antiproliferative activity in A375 cells. While these findings 
reinforce the concept that COX-2 inhibition did not play a role in AM251 cytotoxicity, they 
highlight need for further investigation on the mechanistic bases of AM251-celecoxib combination 
in human cutaneous melanoma. 
It is interesting to note that COX-2-inhibitory function is not required for celecoxib-mediated 
apoptosis, which seems to be associated to the unbalance between pro- e anti-apoptotic proteins, the 
activation of intrinsic apoptotic pathway, and the delayed progression of cells through the G2/M 
phase of the cell cycle [47-48]. Our findings are in line with the previously reported celecoxib-
AM251 molecular similarity [7], which may represent the basis for further investigation on the 
molecular mechanism of AM251. Overall, the results of the current study suggest that AM251 
could be a prototypical compound for the development of promising diarylpyrazole derivatives in 
human cutaneous melanoma. 
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Tables 
Table 1. Primer nucleotide sequences, Ta and amplicon length used for PCR experiments. 
Protein            Primer nucleotide sequences Ta (°C) Amplicon 
length 
β-actin 5'-AACTGGAACGGTGAAGGTGAC-3' (F) 
5'-GACTTCCTGTAACAACGCATCTC-3' (R) 
61 138 pb 
GAPDH 5’-GTGAAGGTCGGAGTCAACG-3’(F)  
5′-GGTGAAGACGGCCAGTGGACT-3’ (R) 
59 301 pb 
TRPA1 5'-TCACCATGAGCTAGCAGACTATTT-3' (F) 
5'-GAGAGCGTCCTTCAGAATCG-3' (R) 
55 74 pb 
Bax 5'-TCTGACGGCAACTTCAACTG-3' (F) 
5'-TTGAGGAGTCTCACCCAACC-3' (R) 
56,6 188 pb 
Bcl-2 5'-TCCATGTCTTTGGACAACCA-3' (F) 
5'-CTCCACCAGTGTTCCCATCT-3' (R) 
56,6 203 pb 
Survivin 5'-ACCAGGTGAGAAGTGAGGGA-3' (F) 
5'-AACAGTAGAGGAGCCAGGGA-3' (R) 
59 309 pb 
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Figure legends 
 
Figure 1. Time-dependency and selectivity of AM251 activity: A) Concentration-dependent cell 
viability decrease to AM251, in A375 melanoma cells after 24, 48 and 72 h exposure to a single 
drug administration; B) Concentration-response curves to AM251 in HDFa cells after 48 and 72h 
exposure. Data are the mean ± SEM from three independent experiments. **P<0.01; ***P<0.001, 
as compared with 24 h (ANOVA followed by the Bonferroni’s multiple comparison test). 
 
Figure 2. Apoptosis induced by AM251 in A375 cells: A) Real-time PCR for the three protein 
involved in apoptosis in A375 treated with AM251 for 48 h. Values were expressed as mean ± 
standard of the mean (SEM) from three separate experiments. ***P<0.001  (ANOVA followed by 
the Bonferroni’s multiple comparison test). B) Western Blot analysis of survivin protein levels 
followed by densitometric assay in A375 cells treated with AM251 for 48 h. C) Analysis of annexin 
V- 7AAD double staining in A375 cells after treatment with AM251 at 5 µM for 72 h or vehicle.  
Upper: Representative dot plots. Lower: bar graph. **P<0.01; ***P<0.001 (ANOVA followed by 
the Bonferroni’s multiple comparison test). D) Nuclear morphology revealed by DAPI staining of 
A375 cells treated with AM251 or vehicle at 48 h. E) [Ca2+]i levels in Fura-2 AM loaded A375 cells 
after treatment for 48 h with AM251 or vehicle (CNTR). Mean values ± SEM (n = 160, P = 0.35 
Student t test). 
 
Figure 3. Cell cycle analyses for asynchronized A375 cells treated with AM251 or vehicle. 
Percentage of A375 cell cycle phases after AM251 at 5 µM for A) 48 and B) 72 h. Data are 
presented as percentage change of cells in the different phases (G0/G1, G2 or S) versus control cells 
and  represent the mean ± SEM of three different experiments.  
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Figure 4. A) cAMP increase in A375 cells after AM251 (5µM) treatment at 48h. Data are the mean 
± SEM from three experiments. *** P<0.001 from Student's t-test. B) Real-time PCR results for 
GPR55 expression, referred to the housekeeping gene beta-actin, after 24 h and 48h after siRNA 
treatment compared to control siRNA-treated cells. *** P<0.001 from ANOVA and Bonferroni test 
C) Concentration-response curve to AM251 in  non-treated cells and in cells silenced with GPR55 
siRNA. D) Ethidium-bromide stained agarose gel revealing TRPA1 gene espression (74pb band) in 
A375 cells E) Absence of changes in Fluo-3 fluorescence during treatment with AM251 (0.1-10 
µM) and increase of signal after calcium loading induced by ionomycin 5 µM. The black and red 
traces indicate the mean pixel values in the regions of interest marked by circles. On the 
pseudocolor scale blue represents 0 and red 255. 
 
Figure 5. (A) Concentration-response curves to celecoxib, rofecoxib and indomethacin in A375 
cells after 48 h exposure. Data are the mean ± SEM from three independent experiments. (B) Cell 
viability after combination of AM251 at 1 and (C) 3 µM with selective (rofecoxib and celecoxib) or 
non-selective (indomethacin) COX inhibitors, compared to single treatments. Values were 
expressed as mean ± standard of the mean (SEM) from three separate experiments. ***P<0.001, 
compared with AM251 alone; ###P<0.001, compared with celecoxib alone (ANOVA followed by 
the Bonferroni’s multiple comparison test).  
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